Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.

MLA

Karas, Spinel, et al. “Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.” Clinical Pharmacology and Therapeutics, vol. 115, no. 5, May 2024, pp. 1162–74. EBSCOhost, https://doi.org/10.1002/cpt.3190.

APA

Karas, S., Mathijssen, R. H. J., van Schaik, R. H. N., Forrest, A., Wiltshire, T., Bies, R. R., & Innocenti, F. (2024). Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model. Clinical Pharmacology and Therapeutics, 115(5), 1162–1174. https://doi.org/10.1002/cpt.3190

Chicago

Karas, Spinel, Ron H J Mathijssen, Ron H N van Schaik, Alan Forrest, Tim Wiltshire, Robert R Bies, and Federico Innocenti. 2024. “Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model.” Clinical Pharmacology and Therapeutics 115 (5): 1162–74. doi:10.1002/cpt.3190.